SG11201804721SA - Modulators of complement activity - Google Patents
Modulators of complement activityInfo
- Publication number
- SG11201804721SA SG11201804721SA SG11201804721SA SG11201804721SA SG11201804721SA SG 11201804721S A SG11201804721S A SG 11201804721SA SG 11201804721S A SG11201804721S A SG 11201804721SA SG 11201804721S A SG11201804721S A SG 11201804721SA SG 11201804721S A SG11201804721S A SG 11201804721SA
- Authority
- SG
- Singapore
- Prior art keywords
- massachusetts
- international
- modulators
- cambridge
- pct
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/30—Syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or carpules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Oscillators With Electromechanical Resonators (AREA)
- Amplifiers (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' Organization International Bureau (43) International Publication Date ..... .....r .,„01 22 June 2017(22.06.2017) WIPO I PCT II (10) 11111111111111111111111 WO International EOM 2017/105939 Publication 1111111111111111111111111t111111111IIIIII Number Al (51) International Patent Classification: #1, Cambridge, Massachusetts 02139 (US). TOBE, Sylvia; A61K 38/12 (2006.01) A61P 37/02 (2006.01) 3 Dodge Street, Cambridge, Massachusetts 02139 (US). A61P 7/00 (2006.01) A61M 5/30 (2006.01) TRECO, Douglas A.; 87 Brantwood Road, Arlington, Massachusetts 02476 (US). (21) International Application Number: PCT/US2016/065228 (74) Agents: WARD, Donna T. et al.; DT Ward, P.C., 142A Main Street, Groton, Massachusetts 01450 (US). (22) International Filing Date: 7 December 2016 (07.12.2016) (81) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (26) Publication Language: English BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (30) Priority Data: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 62/268,360 16 December 2015 (16.12.2015) US KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 62/331,320 3 May 2016 (03.05.2016) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/347,486 8 June 2016 (08.06.2016) US OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (71) Applicant: RA PHARMACEUTICALS, INC. [US/US]; SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, 87 Cambridge Park Drive, Cambridge, Massachusetts TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, 02140 (US). ZW. (72) Inventors: DEMARCO, Steven James; 80 King George (84) Designated States (unless otherwise indicated, for every Drive, Boxford, Massachusetts 01921 (US). ARATA, kind of regional protection available): ARIPO (BW, GH, Michelle Denise; 10 Overlook Ridge Drive, Unit 328, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, ZM, ZW), Eurasian AZ, BY, KG, KZ, RU, Malden, Massachusetts 02148 (US). PARKER, Grace UG, (AM, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, Victoria; 49 Dover St., Apt #48, Somerville, Massachu- DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, setts 02144 (US). RICARDO, Alonso; 35 Pleasant Street, [Continued on next page] (54) Title: MODULATORS OF COMPLEMENT ACTIVITY (57) : The invention present relates to polypeptide modulators of Fig. 9A complement activity, including cyclic Included polypeptide modulators. are -*-- Plasma Concentration - R5000 methods of utilizing such modulators as therapeutics. - 0 - %Hemolysis - R5000 --*-- %Hemoiysis Placebo - 10000 4 8 000 2 Y . tn , ,,, V. _ XJ >: 000 U'1 0 0 8 E 0 4) C 000 r 3 1-1 .4t en CN IC o 1-1 It - -- 1-1 O ei i?\"-9 i 48 96 time (h) 192 2000 i s O WO 2017/105939 Al MIDEDIM01101DERDEEMOM0101111111111111111011110111011110111111 LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Published: SM, GW, TR), KM, OAPI (BF, BJ, CF, CG, CI, ML, MR, NE, SN, TD, TG). CM, GA, GN, GQ, with — with international search report (Art. 21(3)) sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562268360P | 2015-12-16 | 2015-12-16 | |
| US201662331320P | 2016-05-03 | 2016-05-03 | |
| US201662347486P | 2016-06-08 | 2016-06-08 | |
| PCT/US2016/065228 WO2017105939A1 (en) | 2015-12-16 | 2016-12-07 | Modulators of complement activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201804721SA true SG11201804721SA (en) | 2018-07-30 |
Family
ID=57758701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201804721SA SG11201804721SA (en) | 2015-12-16 | 2016-12-07 | Modulators of complement activity |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US10835574B2 (en) |
| EP (3) | EP4218790A1 (en) |
| JP (3) | JP7126940B2 (en) |
| KR (1) | KR20180094913A (en) |
| CN (2) | CN115920000A (en) |
| AU (1) | AU2016370210A1 (en) |
| BR (1) | BR112018012174A2 (en) |
| CA (1) | CA3007772A1 (en) |
| CY (1) | CY1123031T1 (en) |
| DK (2) | DK3389692T3 (en) |
| ES (2) | ES2781551T3 (en) |
| FI (1) | FI3685847T3 (en) |
| HR (2) | HRP20230182T1 (en) |
| HU (1) | HUE061759T2 (en) |
| IL (1) | IL259762B (en) |
| LT (2) | LT3685847T (en) |
| MX (2) | MX2018007352A (en) |
| PL (2) | PL3685847T3 (en) |
| PT (2) | PT3685847T (en) |
| RS (2) | RS60134B1 (en) |
| RU (2) | RU2733720C2 (en) |
| SG (1) | SG11201804721SA (en) |
| SI (2) | SI3685847T1 (en) |
| TW (2) | TWI745320B (en) |
| WO (1) | WO2017105939A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3154561T (en) | 2014-06-12 | 2019-10-25 | Ra Pharmaceuticals Inc | Modulation of complement activity |
| HRP20211824T1 (en) | 2015-01-28 | 2022-03-04 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
| JP7126940B2 (en) | 2015-12-16 | 2022-08-29 | ラ ファーマシューティカルズ インコーポレイテッド | modulator of complement activity |
| TW201836634A (en) | 2016-12-07 | 2018-10-16 | 美商Ｒａ製藥公司 | Modulators of complement activity |
| RU2020117578A (en) | 2017-12-04 | 2022-01-14 | Ра Фармасьютикалз, Инк. | COMPLEMENT ACTIVITY MODULATORS |
| US20220160820A1 (en) | 2019-03-08 | 2022-05-26 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
| CN113710230A (en) * | 2019-04-24 | 2021-11-26 | Ra制药公司 | Compositions and methods for modulating complement activity |
| WO2020247607A1 (en) | 2019-06-04 | 2020-12-10 | Ra Pharmaceuticals, Inc. | Inflammatory disease treatment with complement inhibitors |
| BR112022002522A2 (en) | 2019-09-12 | 2022-08-16 | Ra Pharmaceuticals Inc | TREATMENT OF NEUROLOGICAL DISEASES WITH COMPLEMENT INHIBITORS |
| EP4142738A1 (en) | 2020-04-30 | 2023-03-08 | Alnylam Pharmaceuticals, Inc. | Complement factor b (cfb) irna compositions and methods of use thereof |
| WO2023076451A1 (en) | 2021-10-29 | 2023-05-04 | Alnylam Pharmaceuticals, Inc. | Complement factor b (cfb) irna compositions and methods of use thereof |
Family Cites Families (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4271068A (en) | 1968-05-10 | 1981-06-02 | Ciba-Geigy Corporation | Process for the manufacture of cystine-containing peptides |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4033940A (en) | 1975-11-12 | 1977-07-05 | Armour Pharmaceutical Company | Cyclization of peptides |
| US4216141A (en) | 1978-07-19 | 1980-08-05 | The Salk Institute For Biological Studies | Method for cyclization of peptides |
| JPS6023084B2 (en) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | blood substitute |
| NZ199722A (en) | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US6309669B1 (en) | 1984-03-16 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix |
| DE3675588D1 (en) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE). |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5371109A (en) | 1986-07-01 | 1994-12-06 | Drilletten Ab | Controlled release composition for a biologically active material dissolved or dispersed in an L2-phase |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
| ES2118066T3 (en) | 1989-10-05 | 1998-09-16 | Optein Inc | SYNTHESIS AND ISOLATION, EXEMPTED FROM CELLS, FROM NEW GENES AND POLYPEPTIDES. |
| US5585353A (en) | 1990-02-02 | 1996-12-17 | The Rockefeller University | Antibiotic peptides containing D-amino acids |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| US5843701A (en) | 1990-08-02 | 1998-12-01 | Nexstar Pharmaceticals, Inc. | Systematic polypeptide evolution by reverse translation |
| US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| CA2122732C (en) | 1991-11-25 | 2008-04-08 | Marc D. Whitlow | Multivalent antigen-binding proteins |
| JPH08510325A (en) | 1993-05-28 | 1996-10-29 | カイロン コーポレイション | Methods for selecting biologically active peptide sequences |
| ES2149880T3 (en) | 1993-06-29 | 2000-11-16 | Ferring Bv | SYNTHESIS OF CYCLIC PEPTIDES. |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US5834318A (en) | 1995-05-10 | 1998-11-10 | Bayer Corporation | Screening of combinatorial peptide libraries for selection of peptide ligand useful in affinity purification of target proteins |
| US5912014A (en) | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
| US6720472B2 (en) | 1996-07-12 | 2004-04-13 | University Of Medicine And Dentistry Of New Jersey | HMGI proteins in cancer and obesity |
| US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| US6348584B1 (en) | 1996-10-17 | 2002-02-19 | John Edward Hodgson | Fibronectin binding protein compounds |
| DE69730157T2 (en) | 1996-10-17 | 2005-07-28 | Mitsubishi Chemical Corp. | MOLECULE, WHICH GENOTYP AND PHENOTYPE COMBINED AND ITS APPLICATIONS |
| US5922680A (en) | 1996-10-23 | 1999-07-13 | Ferring, B.V. | Stabilized composition for oral administration of peptides |
| ATE332368T1 (en) | 1997-01-21 | 2006-07-15 | Gen Hospital Corp | SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS |
| US6261804B1 (en) | 1997-01-21 | 2001-07-17 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
| US5990237A (en) | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
| CA2293632C (en) | 1997-06-12 | 2011-11-29 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
| EP0896001A1 (en) | 1997-08-08 | 1999-02-10 | Daicel Chemical Industries, Ltd. | Method for preparing oxytocin antagoniste derivatives, intermediates for the preparation of oxytocin antagonist derivatives and method for preparing the intermediates |
| US6429301B1 (en) | 1998-04-17 | 2002-08-06 | Whitehead Institute For Biomedical Research | Use of a ribozyme to join nucleic acids and peptides |
| CN1313439C (en) | 1998-08-07 | 2007-05-02 | 艾米斯菲尔技术有限公司 | Compounds and compositions for delivering active agents |
| WO2000021559A2 (en) | 1998-10-09 | 2000-04-20 | Musc Foundation For Research Development | Blocking factor b to treat complement-mediated immune disease |
| US6962781B1 (en) | 2000-05-19 | 2005-11-08 | Proteonova, Inc. | In vitro evolution of nucleic acids and encoded polypeptide |
| US7244701B2 (en) | 2000-06-16 | 2007-07-17 | Zealand Phama A/S | Diuretic peptide conjugate |
| EP2266606B1 (en) | 2003-05-15 | 2014-09-10 | Genentech, Inc. | Methods and compositions for the prevention and treatment of sepsis |
| US7348401B2 (en) | 2003-09-10 | 2008-03-25 | Innate Biotech, Inc. | Peptides that inhibit complement activation |
| WO2005053612A2 (en) | 2003-11-26 | 2005-06-16 | Shire Laboratories, Inc. | Micellar systems useful for delivery of lipophilic or hydrophobic compounds |
| US7803931B2 (en) | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
| WO2006066258A2 (en) | 2004-12-17 | 2006-06-22 | Neose Technologies, Inc. | Lipoconjugation of peptides |
| WO2006078161A1 (en) | 2005-01-24 | 2006-07-27 | Pepscan Systems B.V. | Binding compounds, immunogenic compounds and peptidomimetics |
| CA2610502A1 (en) | 2005-03-29 | 2006-10-05 | Cardax Pharmaceuticals, Inc. | Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof |
| BRPI0618160A2 (en) | 2005-05-26 | 2011-08-16 | Univ Colorado | Alternative complement pathway inhibition for treatment of traumatic brain damage, spinal cord damage and related conditions |
| CA2609810C (en) | 2005-06-06 | 2012-05-22 | Camurus Ab | Glp-1 analogue formulations |
| BRPI0619657A2 (en) | 2005-11-04 | 2011-11-08 | Genentech Inc | methods of preventing or ameliorating eye disease, using a complement inhibitor, using a specific siren for a complement system protein and using a nucleic acid encoding a complement system inhibitor |
| EP2359834B1 (en) * | 2006-03-15 | 2016-11-09 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
| EP1876183A1 (en) | 2006-07-04 | 2008-01-09 | Technische Universität München | Minimized small peptides with high affinity for factor VIII and factor VIII-like proteins |
| ES2557056T3 (en) | 2006-10-10 | 2016-01-21 | Regenesance B.V. | Complement inhibition for better nerve regeneration |
| US7736860B2 (en) | 2006-11-09 | 2010-06-15 | Univeristy Of Massachusetts | Methods of identifying compounds for the treatment of sterile inflammation |
| CN101679486A (en) | 2007-03-22 | 2010-03-24 | 诺瓦提斯公司 | c5 antigens and uses thereof |
| US20100015139A1 (en) | 2008-07-10 | 2010-01-21 | Rekha Bansal | METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF |
| CA2680833A1 (en) | 2007-04-30 | 2008-11-13 | Alcon Research, Ltd. | Treatment of age-related macular degeneration using inhibitors of complement factor d |
| SG182165A1 (en) | 2007-06-07 | 2012-07-30 | Genentech Inc | C3b antibodies and methods for the prevention and treatment of complement- associated disorders |
| WO2009014633A1 (en) | 2007-07-20 | 2009-01-29 | Trustees Of The University Of Pennsylvania | Method of treating acute respiratory distress syndrome |
| JP2010540654A (en) | 2007-10-02 | 2010-12-24 | ポテンシア ファーマシューティカルズ， インコーポレイテッド | Sustained delivery of compstatin analogs from gels |
| WO2009067191A2 (en) | 2007-11-16 | 2009-05-28 | The General Hospital Corporation | Methods and compositions for the treatment of hepatitis c virus (hcv) infection |
| EP2278987A4 (en) | 2008-03-28 | 2012-08-22 | Apellis Ag | Modulation and repletion/enhancement of the complement system for treatment of trauma |
| US20100093624A1 (en) | 2008-07-30 | 2010-04-15 | Cosmix Therapeutics Llc | Peptide therapeutics that bind vegf and methods of use thereof |
| AU2009290137A1 (en) | 2008-09-03 | 2010-03-11 | Xenome Ltd | Libraries of peptide conjugates and methods for making them |
| NZ606825A (en) | 2008-11-10 | 2014-10-31 | Alexion Pharma Inc | Methods and compositions for treating complement-associated disorders |
| AU2009230735B1 (en) | 2009-01-08 | 2010-01-21 | Shane Ramodien | Electronic equipment housing |
| RU2600876C2 (en) | 2009-10-16 | 2016-10-27 | Омерос Корпорейшен | Method for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation |
| AU2010314931A1 (en) | 2009-11-05 | 2012-06-21 | Taligen Therapeutics, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis |
| CN102791731B (en) | 2009-12-16 | 2016-04-20 | 诺沃—诺迪斯克有限公司 | GLP-1 sum analogous to general Dedekind sum |
| WO2011106635A1 (en) | 2010-02-25 | 2011-09-01 | The Trustees Of The University Of Pennsylvania | Treatment of sepsis using complement inhibitors |
| EP2563359A1 (en) | 2010-04-30 | 2013-03-06 | Allergan, Inc. | Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase |
| TW201241008A (en) * | 2010-10-01 | 2012-10-16 | Alexion Pharma Inc | Polypeptides that bind to human complement component C5 |
| CA2831563A1 (en) * | 2011-03-29 | 2012-10-04 | Abbvie Inc. | Improved shroud deployment in automatic injection devices |
| NZ746139A (en) | 2011-04-08 | 2023-11-24 | Omeros Corp | Methods for treating conditions associated with masp-2 dependent complement activation |
| US9228003B2 (en) * | 2011-05-05 | 2016-01-05 | Wellstat Immuno Therapeutics, Llc | Complement factor B analogs and their uses |
| WO2012162215A1 (en) | 2011-05-20 | 2012-11-29 | The Trustees Of The University Of Pennsylvania | Promotion of fracture healing using complement inhibitors |
| WO2012174055A1 (en) | 2011-06-13 | 2012-12-20 | The Trustees Of The University Of Pennsylvania | Wound healing using complement inhibitors |
| CN102321170B (en) | 2011-09-14 | 2013-11-13 | 深圳翰宇药业股份有限公司 | Liraglutide variant and conjugate thereof |
| US20140296147A1 (en) | 2011-10-06 | 2014-10-02 | The Medicines Company | Methods of treating or preventing blood loss during surgery using the serine protease inhibitor mdco-2010 |
| LT2817329T (en) | 2012-02-20 | 2019-04-10 | Swedish Orphan Biovitrum Ab (Publ) | Polypeptides binding to human complement c5 |
| US20130246083A1 (en) | 2012-03-16 | 2013-09-19 | Alexion Pharmaceuticals, Inc. | Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor |
| WO2013172954A1 (en) * | 2012-05-17 | 2013-11-21 | Ra Pharmaceuticals, Inc | Peptide and peptidomimetic inhibitors |
| US9579360B2 (en) | 2012-06-20 | 2017-02-28 | The Trustees Of The University Of Pennsylvania | Methods of treating or preventing periodontitis and diseases associated with periodontitis |
| WO2014004733A1 (en) | 2012-06-26 | 2014-01-03 | The Regents Of The University Of California | Composition for lupus nephritis and methods of making and using the same |
| US20150330989A1 (en) | 2012-11-15 | 2015-11-19 | The Brigham And Women's Hospital, Inc. | Method and system for diagnosing and treating preeclampsia |
| US9700633B2 (en) | 2013-01-28 | 2017-07-11 | Jenkem Technology Co., Ltd., Tianjin Branch | Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof |
| US20140234275A1 (en) | 2013-02-15 | 2014-08-21 | Jason Williams | Method for treating als via the increased production of factor h |
| WO2015025312A1 (en) | 2013-08-21 | 2015-02-26 | Cannabics Pharmaceuticals Inc | Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof |
| CN104231085B (en) * | 2013-09-05 | 2017-03-15 | 复旦大学附属肿瘤医院 | Targeting specific complement system inhibitor, its preparation method and application |
| CA2940319A1 (en) | 2014-03-20 | 2015-09-24 | Inflarx Gmbh | Inhibitors of c5a for the treatment of viral pneumonia |
| PT3154561T (en) * | 2014-06-12 | 2019-10-25 | Ra Pharmaceuticals Inc | Modulation of complement activity |
| WO2016094834A2 (en) | 2014-12-12 | 2016-06-16 | Alexion Pharmaceuticals, Inc. | A method for treating a complement mediated disorder caused by an infectious agent in a patient |
| US20160206580A1 (en) | 2015-01-21 | 2016-07-21 | Pacira Pharmaceuticals, Inc. | Multivesicular liposome formulations of tranexamic acid |
| HRP20211824T1 (en) * | 2015-01-28 | 2022-03-04 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
| WO2017035362A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses |
| JP7126940B2 (en) | 2015-12-16 | 2022-08-29 | ラ ファーマシューティカルズ インコーポレイテッド | modulator of complement activity |
| TW201836634A (en) * | 2016-12-07 | 2018-10-16 | 美商Ｒａ製藥公司 | Modulators of complement activity |
| US10376595B2 (en) | 2017-04-03 | 2019-08-13 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5a activity |
| WO2019051436A1 (en) | 2017-09-11 | 2019-03-14 | Ra Pharmaceuticals, Inc. | Formulations for compound delivery |
| RU2020117578A (en) | 2017-12-04 | 2022-01-14 | Ра Фармасьютикалз, Инк. | COMPLEMENT ACTIVITY MODULATORS |
| US20220160820A1 (en) | 2019-03-08 | 2022-05-26 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
| CN113710230A (en) | 2019-04-24 | 2021-11-26 | Ra制药公司 | Compositions and methods for modulating complement activity |
-
2016
- 2016-12-07 JP JP2018531393A patent/JP7126940B2/en active Active
- 2016-12-07 ES ES16823378T patent/ES2781551T3/en active Active
- 2016-12-07 RU RU2018121615A patent/RU2733720C2/en active
- 2016-12-07 EP EP22216383.4A patent/EP4218790A1/en active Pending
- 2016-12-07 TW TW105140483A patent/TWI745320B/en active
- 2016-12-07 PT PT201579166T patent/PT3685847T/en unknown
- 2016-12-07 FI FIEP20157916.6T patent/FI3685847T3/en active
- 2016-12-07 DK DK16823378.1T patent/DK3389692T3/en active
- 2016-12-07 SG SG11201804721SA patent/SG11201804721SA/en unknown
- 2016-12-07 WO PCT/US2016/065228 patent/WO2017105939A1/en active Application Filing
- 2016-12-07 DK DK20157916.6T patent/DK3685847T3/en active
- 2016-12-07 CA CA3007772A patent/CA3007772A1/en active Pending
- 2016-12-07 SI SI201631679T patent/SI3685847T1/en unknown
- 2016-12-07 RS RS20200350A patent/RS60134B1/en unknown
- 2016-12-07 AU AU2016370210A patent/AU2016370210A1/en not_active Abandoned
- 2016-12-07 HU HUE20157916A patent/HUE061759T2/en unknown
- 2016-12-07 PL PL20157916.6T patent/PL3685847T3/en unknown
- 2016-12-07 MX MX2018007352A patent/MX2018007352A/en unknown
- 2016-12-07 KR KR1020187017156A patent/KR20180094913A/en active Search and Examination
- 2016-12-07 ES ES20157916T patent/ES2941640T3/en active Active
- 2016-12-07 CN CN202210878127.8A patent/CN115920000A/en active Pending
- 2016-12-07 RS RS20230218A patent/RS64067B1/en unknown
- 2016-12-07 LT LTEP20157916.6T patent/LT3685847T/en unknown
- 2016-12-07 PT PT168233781T patent/PT3389692T/en unknown
- 2016-12-07 RU RU2020131790A patent/RU2769701C2/en active
- 2016-12-07 EP EP20157916.6A patent/EP3685847B1/en active Active
- 2016-12-07 BR BR112018012174-6A patent/BR112018012174A2/en active Search and Examination
- 2016-12-07 CN CN201680081854.4A patent/CN108697759B/en active Active
- 2016-12-07 US US16/062,653 patent/US10835574B2/en active Active
- 2016-12-07 SI SI201630688T patent/SI3389692T1/en unknown
- 2016-12-07 PL PL16823378T patent/PL3389692T3/en unknown
- 2016-12-07 LT LTEP16823378.1T patent/LT3389692T/en unknown
- 2016-12-07 TW TW110131918A patent/TWI779805B/en active
- 2016-12-07 HR HRP20230182TT patent/HRP20230182T1/en unknown
- 2016-12-07 EP EP16823378.1A patent/EP3389692B1/en active Active
-
2018
- 2018-06-03 IL IL259762A patent/IL259762B/en active IP Right Grant
- 2018-06-14 MX MX2022013454A patent/MX2022013454A/en unknown
-
2020
- 2020-03-27 CY CY20201100292T patent/CY1123031T1/en unknown
- 2020-03-27 HR HRP20200508TT patent/HRP20200508T1/en unknown
- 2020-10-08 US US17/065,560 patent/US11752190B2/en active Active
-
2022
- 2022-08-17 JP JP2022130131A patent/JP7379615B2/en active Active
-
2023
- 2023-11-01 JP JP2023187363A patent/JP2024001300A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201804721SA (en) | Modulators of complement activity | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201804814YA (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
| SG11201808076UA (en) | Facilitating vehicle driving and self-driving | |
| SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201810466PA (en) | Compositions and methods related to engineered fc constructs | |
| SG11201808552XA (en) | T-cell modulatory multimeric polypeptides and methods of use thereof | |
| SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
| SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
| SG11201807720TA (en) | Methods and systems for determining antibiotic susceptibility | |
| SG11201906959RA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201906163TA (en) | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201909224QA (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| SG11201908678XA (en) | Methods and compositions for reduction of immunogenicity | |
| SG11201806133UA (en) | Intermediates in the synthesis of eribulin and related methods of synthesis | |
| SG11201807596YA (en) | Gitr antibodies, methods, and uses | |
| SG11201903885RA (en) | Secure key management | |
| SG11201906139VA (en) | Compositions and methods related to engineered fc constructs |